beta
Trial Radar IA
Lo studio clinico NCT07498686 per RT-QuIC è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease 458 Basato su biomarcatori Innovativo

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT07498686 è uno studio osservazionale per RT-QuIC, attualmente in arruolamento. Avviato il 1 maggio 2023, prevede di arruolare 458 partecipanti. Sotto la guida di Xuanwu Hospital, Beijing, dovrebbe concludersi entro il 23 dicembre 2026. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 27 marzo 2026.
Sommario breve
Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on. The disease is characterized by the abnormal folding of alpha-synuclein (α-syn) in the peripheral and central nervous system, resulting in the production of lewy bodies, lewy neurites, neurons,...Mostra di più
Titolo ufficiale

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease

Patologie
RT-QuIC
Altri ID dello studio
  • 115
Numero NCT
Data di inizio (effettiva)
2023-05-01
Ultimo aggiornamento pubblicato
2026-03-27
Data di completamento (stimata)
2026-12-23
Arruolamento (previsto)
458
Tipo di studio
Osservazionale
Stato
In arruolamento
Parole chiave
PD, MSA, PSP, Neurodegeneration disease, alpha-synuclein
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Control
Control: healthy subjects,
N.D.
PD
parkinson's disease patients
N.D.
MSA
MSA: multiple system atrophy
N.D.
PSP
progressive supranuclear palsy
N.D.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
slope
slope of all Fluorescence value
From enrollment to the end of treatment at 21 weeks
MAX
Maximum fluorescence value
From enrollment to the end of treatment at 21 weeks
Assistente alla partecipazione
Criteri di eleggibilità

Età idonea
Adulto, Adulto anziano
Età minima
18 Years
Sessi idonei
Tutti
Accetta volontari sani

- Grouping criteria for PD patients: All PD patients who join the group need to meet the following conditions at the same time: The diagnosis of primary PD patients is based on the 2015 International Association for Movement Disorders (MDS) Parkinson's disease diagnosis standard, and all patients need to meet the clinical diagnosis or likely Parkinson's disease diagnosis criteria. Quasi; All patients come from the outpatient clinic of Xuanwu Hospital Affiliated to Capital Medical University, and the clinical evaluation and disease diagnosis are completed by a movement disorder specialist. This project is approved by the Ethics Committee of Xuanwu Hospital Affiliated to Capital Medical University. The subjects who participated in the study signed the informed consent form. Fully improve the information of PD patients and form an NSFC 2024 clinical information database. Establish an evaluation scale based on various indicators such as basic demographic data, general disease status and past history and exercise symptom evaluation, including Hoehn & Yahr staging, unified Parkinson's disease assessment scale (MDS- UPDRS), concise mental state examination (MMSE) examination, Monte Lear scale (MOCA), rapid eye movement sleep behavior disorder Hong Kong questionnaire (RBDQ-HK), Hamilton depression scale (HAMD) and anxiety scale (HAMA), integrating a number of sports and non-sports indicators, comprehensively considering and evaluating the patient's condition, for the follow-up relevant Sexual analysis provides accurate and complete clinical information.MSA patients need to meet the MSA clinical diagnosis criteria updated in 2008 by the Europe Multiple System Atrophy Study Group (EMSA-SG). For DLB patients, use the 2017 standard for diagnosis and grouping.

  • Patients with Parkinson's syndrome but not primary PD, patients with brain surgery/deep brain electrode stimulation, or patients diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Illness formulated by the American Association of Mental Illness. PD patients with mild cognitive dysfunction are not excluded.
Xuanwu Hospital, Beijing logoXuanwu Hospital, Beijing
Contatti principali dello studio
Contatto: Weiwei YANG, Ph.D., +86 010-83198271, [email protected]
2 Centri dello studio in 1 paesi

Beijing Municipality

Xuanwu Hospital, Beijing, Beijing Municipality, 100053, China
Completato
Xuanwu Hospital, Beijing, Beijing Municipality, 100053, China
Weiwei YANG, Contatto, +86 010-83198271, [email protected]
In arruolamento